Suarez-Kelly, Lorena P.
Levine, Kala M.
Olencki, Thomas E.
del Campo, Sara E. Martin
Streacker, Elizabeth A.
Brooks, Taylor R.
Karpa, Volodymyr I.
Markowitz, Joseph
Bingman, Anissa K.
Geyer, Susan M.
Kendra, Kari L.
Carson, William E. http://orcid.org/0000-0001-8099-4743
Funding for this research was provided by:
National Institutes of Health (P01 CA095426, P30 CA16058, T32 5T32CA090223-12, T32 CA090223, K24 CA093670, U01 CA76576)
Article History
Received: 1 June 2018
Accepted: 22 January 2019
First Online: 6 February 2019
Compliance with ethical standards
:
: Thomas E. Olencki has received institutional funding from Pfizer, Bristol-Myers Squibb, Regeneron, and Immunocore; Sara E. Martin del Campo has received travel, accommodations, expenses from Medtronic, Intuitive, and Gore; Joseph Markowitz has prior consultant/advisory board roles with Newlink Genetics and Idera; Joseph Markowitz has received institutional funding from Genoptix and Morphogenesis; Kari L. Kendra has received institutional funding from Novartis, Bristol-Myers Squibb, GlaxoSmithKline, Karyopharm Therapeutics and Merck. All other authors have no conflicts of interest to disclose.
: Study was conducted at The Ohio State University under institutional review board approval (OSU-07033). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institution and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Clinical trial was registered with ClinicalTrials.gov, trial number NCT01460875. This article does not contain any studies with animals performed by any of the authors.
: Informed consent for participation, treatment, and the use of the patient data for research/publication was obtained from all individual participants included in this study.